Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

• Results Overview

  Lebrikizumab showed significant improvement in eczema symptoms compared to placebo over 16 weeks, with benefits seen as early as day 2 for itch relief. The medication was generally well-tolerated with few side effects.

• Study Summary

  Num Participants:

  280

  Study Type:

  Rct

  Control Group:

  Placebo Every 2 Weeks

  Efficacy End Points Treatment:

  {'EASI % change': -72.1, 'EASI-75': 33.3, 'IGA 0/1': 33.3, 'Pruritus NRS % change': -47.3}

  Efficacy End Points Control:

  {'EASI % change': -41.1, 'EASI-75': 10.2, 'IGA 0/1': 15.3, 'Pruritus NRS % change': -25.6}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Injection Site Reactions	Low	5.7
  Conjunctivitis	Medium	2.6
  Herpesvirus Infections	Medium	3.5

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Injection Site Reactions	Low	1.9
  Herpesvirus Infections	Medium	3.8